Category News

VideaHealth

VideaHealth and Aspen Dental Execute Major AI Rollout to Elevate Dental Care Across the U.S.

VideaHealth and Aspen Dental Launch One of Dentistry’s Largest AI Rollouts in Record Time, Redefining Patient Care Nationwide VideaHealth, the leading dental AI platform, and Aspen Dental Management, Inc., one of the nation’s largest and fastest-growing dental support organizations, today…

Read MoreVideaHealth and Aspen Dental Execute Major AI Rollout to Elevate Dental Care Across the U.S.
GovRAMP

Butterfly Network Earns GovRAMP and TX-RAMP Information Security Certifications

Butterfly Network Achieves GovRAMP and TX-RAMP Information Security Certifications Butterfly Network, Inc. a digital health company transforming care with semiconductor chip-based ultrasound devices, software and AI, today announced that its Butterfly iQ+/iQ3 and Compass AI™ ultrasound solution have achieved GovRAMP…

Read MoreButterfly Network Earns GovRAMP and TX-RAMP Information Security Certifications
Coya Therapeutics

Coya Therapeutics Schedules Webinar with Medical Experts on ALS Research and Clinical Progress

Coya Therapeutics to Host Webinar with Leading Medical Experts on Amyotrophic Lateral Sclerosis (ALS) Drug Development, Patient Landscape, and Ongoing Clinical Trial Coya Therapeutics, Inc a clinical-stage biotechnology company developing biologics intended to enhance T-cell (Treg) function in patients with…

Read MoreCoya Therapeutics Schedules Webinar with Medical Experts on ALS Research and Clinical Progress
Innovate

Innovate 32 Teams Up with Trivette Osborne & Associates to Grow Tennessee Dental Presence

Innovate 32 Partners with Trivette Osborne & Associates, Expanding its Dental Services Presence in Tennessee Innovate 32 a rapidly expanding, partner-driven dental services organization, announced its partnership with Trivette Osborne & Associates, DDS, PLLC (“T&O”), a leading provider of comprehensive…

Read MoreInnovate 32 Teams Up with Trivette Osborne & Associates to Grow Tennessee Dental Presence
Immunopharma

Estrella Immunopharma Showcases Updated EB103 Data at 2026 ASTCT® & CIBMTR® Tandem Meetings

Estrella Immunopharma Presents Promising Updated Data on EB103 in Oral Presentation at the 2026 Tandem Meetings of ASTCT® & CIBMTR® Estrella Immunopharma, Inc. (Nasdaq: ESLA, ESLAW) a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS® T-cell therapies to treat cancer and autoimmune…

Read MoreEstrella Immunopharma Showcases Updated EB103 Data at 2026 ASTCT® & CIBMTR® Tandem Meetings
VectorY

VectorY Therapeutics Doses First Participant in Phase 1/2 PIONEER-ALS Trial of VTx-002 for ALS

VectorY Therapeutics Announces First Participant Dosed in Phase 1/2 PIONEER-ALS Clinical Trial of VTx-002 in People with Amyotrophic Lateral Sclerosis (ALS) VectorY Therapeutics, a leader in vectorized antibody therapies for neurodegenerative diseases, announced today that the first participant has been…

Read MoreVectorY Therapeutics Doses First Participant in Phase 1/2 PIONEER-ALS Trial of VTx-002 for ALS
ZCG-Backed

ZCG-Backed Unimed Completes Acquisition of Regenboog Shipping Pharmacy

ZCG-Backed Unimed Acquires Regenboog Shipping Pharmacy Universal Maritime Solutions a leading global provider of medical and compliance solutions to the maritime industry, today announced the acquisition of Regenboog Shipping Pharmacy, a Netherlands-based distributor of pharmaceutical products and medical devices serving the…

Read MoreZCG-Backed Unimed Completes Acquisition of Regenboog Shipping Pharmacy
Evinova

Evinova and Bristol Myers Squibb Partner Strategically to Enhance Clinical Development Using AI

Evinova and Bristol Myers Squibb Forge Strategic Collaboration to Optimize Clinical Development with Artificial Intelligence Evinova today announced that Bristol Myers Squibb has signed an agreement to optimize clinical trials with Evinova’s AI-native clinical development platform. Under the terms of…

Read MoreEvinova and Bristol Myers Squibb Partner Strategically to Enhance Clinical Development Using AI
Johnson & Johnson

Johnson & Johnson Shares Early OMNY-AF Pilot Study Results at the 2026 AF Symposium

Johnson & Johnson Presents Early Outcomes from the OMNY-AF Pilot Study at 2026 AF Symposium Johnson & Johnson today announced 12-month pilot-phase data from the OMNY-AF study, evaluating the investigational OMNYPULSE Platform for the treatment of symptomatic paroxysmal atrial fibrillation…

Read MoreJohnson & Johnson Shares Early OMNY-AF Pilot Study Results at the 2026 AF Symposium
DISTALS

Rapid Medical’s DISTALS Trial Shows Strong Results, Highlighting Superior Reperfusion with TIGERTRIEVER™ 13

Rapid Medical’s DISTALS Trial Overwhelmingly Positive, Demonstrating Superior Reperfusion with TIGERTRIEVER™ 13 in Medium Vessel Stroke Rapid Medical™, a leading developer of active endovascular devices, today announced late-breaking results from the DISTALS multicenter, randomized controlled trial showing that TIGERTRIEVER™ 13 achieved superior…

Read MoreRapid Medical’s DISTALS Trial Shows Strong Results, Highlighting Superior Reperfusion with TIGERTRIEVER™ 13